CBL-0137 is under clinical development by Incuron and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs for Melanoma have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CBL-0137’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CBL-0137 (CBLC-137) is under development for the treatment of melanoma (second line therapy), sarcoma (second line therapy) and resistant or refractory advanced solid cancers, osteosarcoma and pediatric diffuse intrinsic pontine glioma. It is administered through oral, intraarterial, and intravenous routes. The drug candidate is a carbazole-derived compound. It is developed based on Curaxin technology.
It was also under development for the treatment of pancreatic ductal adenocarcinoma, colon adenocarcinoma, renal cell carcinoma, human non-small cell lung cancer, mammary gland adenocarcinoma, pancreatic cancer, head and neck cancer, prostate cancer, melanoma, glioblastoma, neuroblastoma, glioblastoma multiforme (second line therapy), hematological malignancies like diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, Hodgkin lymphoma (B -cell Hodgkin lymphoma), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (all, acute lymphoblastic leukemia), acute myelocytic leukemia (aml, acute myeloblastic leukemia), multiple myeloma (Kahler disease), B -cell non-Hodgkin lymphoma and human African trypanosomiasis.
Incuron is a biotechnology company developing anticancer therapies. Incuron is headquartered in Moscow, Russia.
For a complete picture of CBL-0137’s drug-specific PTSR and LoA scores, buy the report here.